NUWE stock forecast, quote, news & analysis
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems... Show more
Why Nuwellis (NUWE) Stock Is Down -37% in the Last 30 Days
Key Takeaways
- Nuwellis (NUWE) shares declined roughly 37% over the trailing 30 days, falling from about $0.87 to approximately $0.55 per share.
- The drop extends a longer multi-month downtrend tied to dilutive financing and a reverse split completed during the summer, rather than a single adverse event.
- Operational fundamentals have improved, with double-digit revenue growth and gross margin expansion, but these gains have not yet reversed negative price momentum.
- The stock is a thinly traded micro-cap with low institutional ownership, making it vulnerable to outsized price swings on modest trading volume.
- Investors continue to watch the pediatric label expansion, new product development, and cash runway into 2027 as key forward-looking catalysts.
Nuwellis (NUWE) Company Overview and Market Position
Nuwellis, Inc. is a Minnesota-based medical technology company focused on fluid management for patients with cardiorenal conditions. Its flagship product, the Aquadex SmartFlow System, provides controlled ultrafiltration to remove excess fluid in patients whose fluid overload does not respond adequately to medical management, including diuretics. The system is cleared for use in adult and pediatric patients weighing 20 kilograms or more, administered by trained healthcare providers in clinical settings.
The company has built a differentiated position in pediatric fluid management, a category that represented approximately half of its U.S. revenue in 2025, with a footprint spanning 47 centers nationwide, including six of the top 10 children's hospitals as ranked by U.S. News & World Report. Nuwellis is also expanding into adult critical care and heart failure. Investors follow the stock for its recurring consumables revenue model, its pediatric growth strategy, and development-stage technologies such as the Vivian pediatric CRRT platform and ClarityPRIME kidney-function monitoring system.
Nuwellis (NUWE) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Nuwellis shares have fallen approximately 37%, declining from roughly $0.87 to a recent close near $0.55. The move has been characterized by persistent selling pressure in a low-liquidity, micro-cap name, with only brief, short-lived rallies that quickly faded.
The quarterly picture is steeper still. In late July the stock traded around $1.93, and it has since declined to roughly $0.55, a drop of more than 70% over the period. This longer trend reflects the lingering after-effects of a reverse split executed to maintain Nasdaq listing compliance and dilutive share-and-warrant financing completed during the summer months. The result has been a sustained downtrend even as the company has reported improving operating metrics.
What Drove NUWE Stock Price in the Last 30 Days
The 30-day decline did not stem from a single discrete negative announcement. Instead, it reflects continued downward pressure in a thinly traded micro-cap that is still absorbing the consequences of dilutive financing and a reverse split earlier in the year. With institutional ownership reported near 3% and a market capitalization in the low single-digit millions of dollars, relatively modest selling activity can move the share price sharply.
A brief rally in mid-September, which coincided with the company's disclosure that it had sold 31 Aquadex consoles year-to-date, quickly unwound. Subsequent operational announcements during the period, including participation in four October medical conferences and the scheduling of a Pediatric Medical & Nursing Advisory Board for the Vivian CRRT system, were not sufficient to reverse the downtrend. The net result has been a steady erosion of the share price despite a generally positive stream of company news.
What Drove NUWE Stock Performance Over the Last Quarter
Over the past quarter, the dominant narrative has been financial rather than operational. Nuwellis completed a reverse split and raised additional capital through share and warrant sales, steps that preserved its Nasdaq listing and extended its cash runway but meaningfully diluted existing shareholders. This financing-driven pressure has outweighed tangible business progress.
On the operating side, results have been encouraging. Second-quarter 2026 revenue rose 14% year over year to approximately $1.97 million, with U.S. revenue up 17%, while gross margin improved to 76% from 56% a year earlier. The company has also highlighted a strengthened cash position of approximately $8.8 million as of late August 2026 and a projected runway into the third quarter of 2027. Despite these improvements, investor sentiment has remained cautious, reflecting the market's focus on dilution, cash burn, and the company's very small revenue base relative to its losses.
Trending AI Robots
For traders seeking a data-driven approach to navigating volatile small-cap names, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary by strategy, timeframe, and performance metrics, allowing users to compare approaches suited to different market conditions. Whether you are tracking momentum, mean-reversion, or longer-term signals, the platform provides tools to explore how AI-driven systems interpret real-time market data. Visit the Trending AI Robots page to review the strategies currently capturing attention.
NUWE Stock Forecast Drivers: What Investors Should Watch Next
Several factors will likely shape Nuwellis shares in the months ahead. The company's third-quarter 2026 earnings report, anticipated in mid-November, will offer the next update on revenue growth, console placements, gross margin, and cash burn. Investors will also watch the proposed Aquadex label expansion from the current 20-kilogram threshold down to 5-kilogram patients, with a regulatory submission planned for the fourth quarter of 2026.
Broader themes include continued adoption of the Aquadex platform across pediatric, critical care, and heart failure markets; progress on the Vivian pediatric CRRT system and the ClarityPRIME monitoring product, the latter expected to launch in 2027; and the company's ability to manage dilution and cash consumption while sustaining its stated runway into 2027. Macroeconomic conditions affecting small-cap and medical technology valuations, as well as competitive dynamics in the renal and fluid-management space, also remain relevant. These considerations are informational in nature and should not be interpreted as investment advice.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for NUWE turns negative, indicating new downward trend
NUWE saw its Momentum Indicator move below the 0 level on September 28, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In 81 of the 82 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUWE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NUWE entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 72 cases where NUWE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
Following a +1.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where NUWE advanced for three days, in 146 of 183 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
NUWE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.806) is normal, around the industry mean (2.923). P/E Ratio (0.000) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.007) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. NUWE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUWE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of heart assist devices
Industry MedicalNursingServices